Yulia Volchek

414 citations

29 papers · 285 indexed · h-index 9

Impact in

Hematology top 5%
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 27
- Chronic Myeloid Leukemia Treatments 18
- Acute Myeloid Leukemia Research 12
- Hematopoietic Stem Cell Transplantation 12
Genetics 11
- Chronic Lymphocytic Leukemia Research 8

Co-authors: Avichai Shimoni Arnon Nagler Ronit Yerushalmi Noga Shem‐Tov Maya Koren‐Michowitz Abraham Avigdor Ivetta Danylesko A Nagler
Journals: Blood (13 papers)Biology of Blood and Marrow Transplantation (4 papers)Annals of Hematology (2 papers)Oncotarget (2 papers)Acta Haematologica (1 paper)
Partner nations: Israel United States Italy

In The Last Decade

Yulia Volchek

28 papers receiving 282 citations

Peers

Countries citing papers authored by Yulia Volchek

Since Specialization

Citations

This map shows the geographic impact of Yulia Volchek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulia Volchek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulia Volchek more than expected).

Fields of papers citing papers by Yulia Volchek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulia Volchek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulia Volchek. The network helps show where Yulia Volchek may publish in the future.

Co-authors

The 25 scholars most cited alongside Yulia Volchek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yulia Volchek Line = papers co-authored together Yulia Volchek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study Acta Haematologica ·Adrian Duek, red. Marcel de Koning .., SamuelUwale Eyesan, Е.А. Суханов, Hasan Maqbool, І. В. Доля, Adi Shacham Abulafia, Amos Cohen, Noa Lavi, Aaron Ronson, 麻美安田, Derek R. George, Jonathan Canaani, Yulia Volchek, Ronit Leiba, Santis Brante	2024	1
2	Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma Blood ·Muhıt Özcan, Eva González‐Barca, Tae Min Kim, Ewa Paszkiewicz‐Kozik, Jan Maciej Zaucha, Stefan Hohaus, Marco Ladetto, Caterina Patti, Sebastian Giebel, Tadeusz Robak, Ömür Gökmen Sevindik, Yulia Volchek, Benedetta Puccini, L. Octavio Lerma, Raúl Córdoba, Gabriela Córdoba Domínguez, S Shah, Zhang Xueyua, Rushdia Z. Yusuf, David Lavie	2024	1
3	Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study Clinical Lymphoma Myeloma & Leukemia ·José Luis Ramos Quirarte, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Kunkerkar R.L., Liat Shargian, Cristiano Machado Gualhardi, Evgeni Chubar, Joshua Gans, Uri Rozovski	2018	16
4	Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors Blood ·Ohad Benjamini, Masatugu Fujie, Elena Ribakovsky, Meirav Kedmi, Adrian Duek, Drorit Merkel, Merav Leiba, Ivetta Danylesko, Noga Shem‐Tov, Ronit Yerushalmi, Avichai Shimoni, Abraham Avigdor, Arnon Nagler, Yulia Volchek	2016	6
5	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post–Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients Biology of Blood and Marrow Transplantation ·Maya Koren‐Michowitz, Avichai Shimoni, 岡本知子, A Nowak, В.В. Еремин, Yulia Volchek, Ninette Amariglio, Enrico Gottardi, Giuseppe Saglio, Arnon Nagler	2015	2
6	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma Annals of Hematology ·Abraham Avigdor, Hui XiaoPing, Meirav Kedmi, Josep Ribera Florit, Miriam Berkowicz, JP Enis, Abraham Kneller, Drorit Merkel, Yulia Volchek, Tima Davidson, Elinor Goshen, Sara Apter, Avichai Shimoni, Isaac Ben‐Bassat, Arnon Nagler	2014	41
7	Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia Cancer ·Avichai Shimoni, Yulia Volchek, Maya Koren‐Michowitz, Nira Varda‐Bloom, Raz Somech, Noga Shem‐Tov, Ronit Yerushalmi, Arnon Nagler	2014	39
8	Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation Annals of Hematology ·Maya Koren‐Michowitz, Ma Junrong, Arie Apel, Noga Shem‐Tov, Ronit Yerushalmi, Yulia Volchek, Abraham Avigdor, Avichai Shimoni, Arnon Nagler	2014	8
9	The Use of Tevagrastim (Biosimilar Filgrastim XMO2) for Hematopoietic Stem Cell Mobilization in HLA Matched Sibling Donors for Allogeneic Stem Cell Transplantation to AML/MDS Patients Biology of Blood and Marrow Transplantation ·Ivetta Danylesko, 幸隆滝谷, Yaqun Ni, Ronit Yerushalmi, Noga Shem‐Tov, Yulia Volchek, Avichai Shimoni, Arnon Nagler	2014	3
10	Nilotinib-Associated Acute Pancreatitis Annals of Pharmacotherapy ·Tal Engel, Dan Justo, Michal Amitai, Yulia Volchek, Haim Mayan	2013	12
11	The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients Blood ·Ivetta Danylesko, 幸隆滝谷, Yaqun Ni, Ronit Yerushalmi, Noga Shem‐Tov, Yulia Volchek, Avichai Shimoni, Arnon Nagler	2013	2
12	Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced Leukemia ·Avichai Shimoni, Noga Shem‐Tov, Angela Chetrit, Yulia Volchek, Hans Ch. Dechêne, Abraham Avigdor, Siegal Sadetzki, Ronit Yerushalmi, Arnon Nagler	2012	42
13	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity Bone Marrow Transplantation ·Avichai Shimoni, Noga Shem‐Tov, Yulia Volchek, Ivetta Danylesko, Ronit Yerushalmi, A Nagler	2012	39
14	Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC Hematological Oncology ·Maya Koren‐Michowitz, Yulia Volchek, Elizabeth Naparstek, سامی ماجد محمود العطار, Itai Levi, Jacob M. Rowe, Avichai Shimoni, Arnon Nagler	2012	34
15	Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option Blood ·Avichai Shimoni, Noga Shem‐Tov, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler	2012	1
16	Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Blood ·Arnon Nagler, Yulia Volchek, W.F. Blom, Raz Somech, Ronit Yerushalmi, Avichai Shimoni	2011	3
17	Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced Blood ·Avichai Shimoni, Noga Shem‐Tov, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler	2011	1
18	Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds; Relative Outcomes Depend On Disease Status at Transplantation. Blood ·Avichai Shimoni, Claybourne Carson, Noga Shem‐Tov, Izhar Hardan, Yulia Volchek, Mustafa Yazar, Ronit Yerushalmi, Arnon Nagler	2009	1
19	Long-Term Survival and Late Events After Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and Mds; Comparable Results with Myeloablative Conditioning. Blood ·Avichai Shimoni, Claybourne Carson, Noga Shem‐Tov, Izhar Hardan, Yulia Volchek, Mustafa Yazar, Ronit Yerushalmi, Arnon Nagler	2009	1
20	Renal extramedullary haematopoiesis mimicking renal lymphoma on computed tomography Clinical Radiology ·Maya Galperin-Aizenberg, Yulia Volchek, Wataru Ootani, U. Kullik, Zeev V. Maizlin, ANTLER, Gabriela Gayer	2006	10

About Yulia Volchek

Yulia Volchek is a scholar working on Hematology, Genetics, Rheumatology, Oncology and Public Health, Environmental and Occupational Health, having authored 29 papers that have together received 285 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (18 papers), Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (12 papers), Chronic Lymphocytic Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (7 papers), Eosinophilic Disorders and Syndromes (5 papers), CAR-T cell therapy research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hematology (204 citations), Genetics (99 citations), Oncology (81 citations), Pathology and Forensic Medicine (52 citations) and Public Health, Environmental and Occupational Health (79 citations). Yulia Volchek has collaborated with scholars based in Israel, United States and Italy. Frequent co-authors include Avichai Shimoni, Arnon Nagler, Ronit Yerushalmi, Noga Shem‐Tov, Maya Koren‐Michowitz, Abraham Avigdor, Ivetta Danylesko, A Nagler, Nira Varda‐Bloom and Raz Somech. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Annals of Hematology, Oncotarget and Acta Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact